Study in Male / Postmenopausal Female Participants With Mild to Moderate Arterial Hypertension to Investigate Safety, Tolerability and Pharmacokinetics of Single and Multiple Doses of BAY 3283142 in a Randomized, Multi-center, Placebo-controlled, Single-blind, Group Comparison Design
Latest Information Update: 19 May 2023
At a glance
- Drugs Nurandociguat (Primary)
- Indications Hypertension
- Focus Adverse reactions
- Sponsors Bayer
Most Recent Events
- 16 May 2023 Status changed from active, no longer recruiting to completed.
- 31 Mar 2023 Planned End Date changed from 17 Mar 2023 to 6 Apr 2023.
- 08 Mar 2023 Planned End Date changed from 28 Feb 2023 to 17 Mar 2023.